Impact of the <i>CYP2C8</i> *<i>3</i> polymorphism on the drug–drug interaction between gemfibrozil and pioglitazone

Abstract

CYP2C8*3 is associated with decreased pioglitazone plasma exposure in vivo and significantly influences the pharmacokinetic magnitude of the gemfibrozil-pioglitazone drug-drug interaction. Additional studies are needed to evaluate the impact of CYP2C8 genetics on the pharmacokinetics of other CYP2C8-mediated drug-drug interactions.